Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down

Company Overview - Intellia is a genome editing company focused on developing CRISPR/Cas9-based therapeutics, with its lead candidate NTLA-2001 targeting transthyretin (ATTR) amyloidosis [3] - NTLA-2001 is part of a co-development and co-promotion agreement with Regeneron, where Regeneron shares 25% of the development costs and commercial profits [3][11] Recent Developments - The company appointed Edward Dulac as the new CFO, effective July 22, 2024, succeeding Glenn Goddard, who will step down on June 30, 2024 [1][9][10] - Intellia reported encouraging long-term data from the phase I portion of its study evaluating NTLA-2002 for hereditary angioedema (HAE) [4][13] Financial Performance - Year to date, shares of Intellia have declined by 24.8%, while the industry has seen a decline of 4.6% [2] - The company currently holds a Zacks Rank 3 (Hold) [6] Clinical Trials and Milestones - NTLA-2001 is being studied for two indications: ATTR amyloidosis with polyneuropathy and ATTR amyloidosis with cardiomyopathy, with the phase III MAGNITUDE study ongoing [12] - Several clinical milestones are expected later in the year, which may impact the company's growth trajectory [5]